443 related articles for article (PubMed ID: 35864467)
1. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
[TBL] [Abstract][Full Text] [Related]
4. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
8. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
Duan JJ; Ning T; Bai M; Zhang L; Li HL; Liu R; Ge SH; Wang X; Yang YC; Ji Z; Wang FX; Sun YS; Ba Y; Deng T
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):967-972. PubMed ID: 37968083
[No Abstract] [Full Text] [Related]
10. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
[TBL] [Abstract][Full Text] [Related]
11. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
[TBL] [Abstract][Full Text] [Related]
13. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
17. Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Matsubara Y; Masuishi T; Ogata T; Nakazawa T; Kato K; Nozawa K; Narita Y; Honda K; Bando H; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1123-1129. PubMed ID: 35314873
[TBL] [Abstract][Full Text] [Related]
18. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]